A study for percutaneous paricalcitol injection in the treatment of chronic kidney disease associated tertiary hyperparathyroidism

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900025628

Enrollment

Unknown

Registered

2019-09-03

Start date

2019-09-02

Completion date

Unknown

Last updated

2019-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic kidney disease associated tertiary hyperparathyroidism

Interventions

1:percutaneous paricalcitol injection

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. PTH more than 400pg/ml; 2. Resistant to active vitamin D therapy for more than 3 months; 3. Parathyroid gland nodule or adenoma on ultrasonography; 4. Patient who have given informed consent.

Exclusion criteria

Exclusion criteria: 1. Parathyroid gland nodule or adenoma located where ultrasonographic-guided puncture is impossible; 2. Patient who have difficulty in keeping the proper position for puncture; 3. Very low platelet level or severe bleeding tendency.

Design outcomes

Primary

Measure	Time frame
parathyroid hormone;volume of parathyroid gland nodule/adenoma;	—

Countries

China

Contacts

Public ContactSu Baihai

West China Hospital, Sichuan University

imsbh@163.com+86 18980601210

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026